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INTRODUCTION
Cerebral venous thrombosis (CVT) is less frequent than other 
types of strokes and has a different clinical presentation and 
etiologies. 
Numerous conditions are known to cause CVT, such as pro-
thrombotic conditions, infection, inflammatory disease, hema-
tologic disease, malignancy, pregnancy, puerperium state, and 
drugs.1 Therefore, thorough etiologic investigations are need-
ed to determine the cause of CVT. However, its underlying risk 
factors are not found in approximately 13% of adult patients with 
CVT.2 Finasteride, a 5α-reductase inhibitor, is used to treat be-
nign prostate hypertrophy as well as androgenetic alopecia, 
and it has been reported to induce CVT as a complication.3 
Dutasteride is a new 5α-reductase inhibitor with the same in-
dication as finasteride. Herein, we report a case of CVT caused 
by dutasteride use. Informed consent was obtained from the 
patient.
CASE REPORT
A 26-year-old male was admitted to the neurology department 
due to headache and horizontal diplopia. He had no previous 
illness or trauma history and was non-smoker. The patient had 
been taking 0.5 mg of dutasteride every other day for 9 months 
to treat alopecia. He did not take any medication except dutas-
teride. A headache developed 7 months after he began taking 
the medication, and horizontal diplopia occurred 1 month af-
ter the onset of headache. Pulsatile headache with dizziness 
initially started from the occipital area and progressed to the 
bi-frontal and temporal areas. The patient complained of hor-
izontal diplopia when he looked laterally to either side. Neu-
rologic examination showed no weakness, ataxia, sensory dis-
turbance, or visual field defect.
Initial fundus examination showed bilateral papilledema and 
retinal hemorrhage (Fig. 1A). To determine the cause of intra-
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cranial hypertension, brain magnetic resonance imaging (MRI) 
was performed on the day of admission, and it revealed throm-
bosis in the left jugular vein, sigmoid, and transverse sinuses 
(Fig. 1B). The patient showed no fever or specific findings based 
on blood tests for infectious conditions, including white blood 
cell count, erythrocyte sedimentation rate, and C-reactive pro-
tein. In addition, autoimmune antibodies, D-dimer, fibrino-
gen, antithrombin III, protein C, protein S, prothrombin time, 
activated partial thromboplastin time, and platelet count were 
normal. Serum estradiol level, which was measured 4 days af-
ter the discontinuation of dutasteride, was 14.2 pg/mL (normal 
range for male, 11.3–43.2). 
There was no specific drug history to explain cerebral venous 
thrombosis other than dutasteride use. Therefore, dutasteride 
was discontinued, and intravenous anticoagulation was start-
ed to treat CVT. In addition, mannitol was used due to the bi-
lateral papilledema for 10 days. We also used 250 mg of acet-
azolamide twice a day to alleviate intracranial hypertension for 
5 months. After 1 week of intravenous anticoagulation, 7.5 mg 
of warfarin was given daily. After 6 weeks of oral anticoagula-
tion treatment, the patient’s symptoms were relieved, and bi-
lateral papilledema was improved (Fig. 1C). Follow-up brain 
MRI performed at 9 months after anticoagulation treatment 
showed resolution of sinus thrombosis in the left sigmoid and 
transverse sinuses (Fig. 1D). Oral anticoagulation treatment 
was discontinued after follow-up MRI, and the patient had no 
symptoms since then.
DISCUSSION
Several types of drugs can cause CVT. Oral contraceptives are 
known to increase the risk of sinus thrombosis due to their pro-
thrombic effects. In addition, asparaginase, cisplatin, metho-
trexate, lithium, and steroids can cause CVT.4 In several case 
reports, finasteride was found to cause CVT. Finasteride is a 
competitive inhibitor of type II 5α-reductase and an intracel-
lular enzyme that converts the androgen testosterone into 
5α-dihydrotestosterone. As a result of this mechanism, finas-
teride could increase serum estrone and estradiol levels and 
elevate the risk of CVT.5,6
In the present case, the patient also took dutasteride, a se-
lective inhibitor of the type I and II isoforms of 5α-reductase, 
which is more widely expressed and found in the skin, liver, 
and kidneys. The patient did not have other prothrombotic 
conditions, such as infection, inflammatory disease, malignan-
cy, or hematologic disease, and was not using any medications 
that could cause CVT, except dutasteride. Previous studies did 
not show consistent evidence of a significant association be-
tween dutasteride therapy and risk of cardiovascular adverse 
events.7,8
In this case, symptoms including headache, dizziness, and 
horizontal diplopia, which indicate intracranial hypertension, 
occurred progressively and were relieved with anticoagulation 
treatment, as in the previously reported CVT cases. Although 
there have been several studies that reported cases of CVT 
caused by specific drugs, dutasteride has not yet been report-
ed to cause CVT. The present case indicates that the risk of 
Fig. 1. (A) Initial fundus photograph shows bilateral papilledema and retinal hemorrhage. (B) Initial brain magnetic resonance imaging (MRI) shows throm-
bosis (arrows) in the left jugular vein, sigmoid, and transverse sinuses. (C) The papilledema is apparently improved after 6 weeks of anticoagulation treatment. 
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CVT should be considered when dutasteride is prescribed for 
alopecia, benign prostate hyperplasia, or prostate cancer. In 
addition, a detailed history should be taken for patients who 
present with headache and other neurologic symptoms.
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